Cue Biopharma, INC 8-K filings

Cue Biopharma has been notified by Nasdaq that its stock price has fallen below the minimum bid price of $1.00, potentially leading to delisting if not rectified.

Cue Biopharma is shifting its focus to autoimmune programs, implementing a 25% workforce reduction, and reducing executive pay to extend its cash runway into mid-2025.

Cue Biopharma appointed Michael J. Fox to its board of directors and held its 2024 annual meeting, where key proposals were approved.

Cue Biopharma announced its first quarter 2024 financial results, highlighting increased collaboration revenue and advancements in its clinical and preclinical programs.